Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
2.77 USD +2.21% Intraday chart for Lyell Immunopharma, Inc. +1.09% +42.78%
May. 06 Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
May. 06 Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
GL
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows
MT
Lyell Immunopharma: Q1 Earnings Snapshot
AQ
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q1 Revenue $3,000
MT
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
GL
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
GL
North American Morning Briefing : Stock Futures -2-
DJ
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000
MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
GL
Lyell Immunopharma Announces Participation in March Investor Conferences
GL
Lyell Immunopharma Announces Participation in March Investor Conferences
AQ
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.
CI
MaxCyte's strategic platform licences redeem otherwise modest results
AN
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
GL
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index
CI
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. News Lyell Immunopharma, Inc.